Brief: Femasys Completes Enrollment Of Femaseed Pivotal Trial In Support Of Commercial Launch
28/11/2023 15:17
Nov 28 (Reuters) - Femasys Inc FEMY.O :
* FEMASYS INC. COMPLETES ENROLLMENT OF FEMASEED PIVOTAL
TRIAL IN
SUPPORT OF COMMERCIAL LAUNCH
* FEMASYS INC - COMMERCIAL LAUNCH PLANNED FOR EARLY 2024
* FEMASYS INC - TOPLINE RESULTS FROM FEMASEED(®) PIVOTAL
TRIAL
EXPECTED IN 1H 2024
Source text for Eikon: ID:nGNX74nhnH
Further company coverage: FEMY.O
Recent news on Femasys
See all newsBrief: Femasys - Files For Resale Of Up To 28,124,997 Shares Of Common Stock - SEC Filing
Brief: Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview